Recently Featured

Biopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?

May 30, 2026
With the FDA now rudderless following the announcement of Commissioner Marty Makary, M.D.’s impending departure, the biopharma sector is coalescing around Richard Pazdur, M.D., as a prime candidate for the agency’s leadership. Pazdur, who previously served as the FDA’s top drug regulator, is viewed by many industry leaders as a logical choice to steer the…

Zydus to acquire Assertio in $166m deal

May 30, 2026
Zydus Lifesciences has announced its intention to acquire all outstanding common shares of Assertio in a deal valued at $166.4 million, facilitated through its subsidiary Zydus Worldwide DMCC. This strategic acquisition underscores Zydus’s commitment to expanding its portfolio and enhancing its market presence in the pharmaceutical sector. The acquisition of Assertio, known for its specialty…

Fresenius Medical Care Issues Class 4 Medicines Defect Notification for Peritoneal Dialysis Solution

May 29, 2026
Fresenius Medical Care Deutschland GmbH has issued a Class 4 Medicines Defect Notification concerning its balance solution containing 2.3% glucose and 1.25 mmol/l calcium, intended for peritoneal dialysis. The notification highlights a critical error in the Braille printed on the outer label, which may lead to misinterpretation of the product’s usage instructions. This defect is…

Sun recalls US chemotherapy batch, citing glass particle contamination concerns

May 29, 2026
Generics juggernaut Sun Pharma is recalling a specific lot of a chemotherapy drug in the United States due to concerns over glass particle contamination. This action highlights a recurring issue within the pharmaceutical industry, where particulate contamination has increasingly become a focus for regulatory bodies such as the FDA. The recall not only raises questions…

Ongoing Cases